

PTO/SB/08A

AUG 15 2003

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/857,994				
Filing Date	October 5, 2001				
Confirmation Number	Unknown				
First Named Inventor	John P. McKearn et al.				
Group Art Unit	1646				
Examiner Name	Unknown				
Sheet	1	of	13	Attorney Docket No.	PHA 4295 (3167/6Z)

TECH CENTER 1600  
AUG 23 2003  
RECEIVED  
1600-200

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	1.	4,100,274		Dutta et al.	07-11-1978
	2.	4,105,681		Bollag et al.	08-08-1978
	3.	4,140,707		Cleare et al.	02-20-1979
	4.	4,215,215		Bollag et al.	07-29-1980
	5.	4,310,666		Zee-Cheng et al.	01-12-1982
	6.	4,472,382		Labrie et al.	09-18-1984
	7.	4,596,797		Schweikert et al.	06-24-1986
	8.	5,250,683		Holton et al.	10-05-1993
	9.	5,254,703		Holton	10-19-1993
	10.	5,272,171		Ueda et al.	12-21-1993
	11.	5,319,112		Kingston et al.	06-07-1994
	12.	5,344,991		Reitz et al.	09-06-1994
	13.	5,455,270		Kaplan et al.	10-03-1995
	14.	5,633,016		Johnson	05-27-1997
	15.	5,686,419		Powers et al.	11-11-1997
	16.	5,696,131		Baguley et al.	12-09-1997

Examiner Signature	Date Considered
--------------------	-----------------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	09/857,994
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1646
Examiner Name	Unknown
Attorney Docket No.	PHA 4295 (3167/6Z)

2	of	13
---	----	----

17.	5,733,909	Black et al.	03-31-1998
18.	5,767,142	LaVoie et al.	06-16-1998
19.	5,824,699	Kreft et al.	10-20-1998
20.	5,837,696	Golub et al.	11-17-1998
21.	5,869,524	Failli	02-09-1999
22.	5,952,381	Chen et al.	09-14-1999

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
23.	DE	195 48 798	A1	Dr. Karl Thomae GmbH	07-03-1997	A	
24.	DE	196 13 933	A1	Merck Patent GmbH	10-09-1997	A	
25.	DE	196 26 701	A1	Hoechst AG	01-08-1998	A	
26.	EP	0 010 458	A1	ANVAR	04-30-1980	A	
27.	EP	0 054 168	A1	Klinge Pharma GmbH & Co.	06-23-1982	A	
28.	EP	0 095 875	A2	Farmos Group Ltd.	12-07-1983		
29.	EP	0 165 904	A2	Ciba-Geigy AG	12-27-1985	A	
30.	EP	0 199 636	A1	C.I.R.D.	10-29-1986	A	
31.	EP	0 236 940	B1	Ciba-Geigy AG	09-16-1987		
32.	EP	0 260 744	B1	Janssen Pharmaceutica N.V.	03-23-1988		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..


SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED  
TECH CENTER 1600  
AUG 2 3 2003  
1600  
2003

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	09/857,994
Filing Date	October 5, 2000
Confirmation Number	Unknown
First Named Inventor	John P. McKearney et al.
Group Art Unit	1646
Examiner Name	Unknown
Sheet 3 of 13	Attorney Docket No. PHA 4295 (3167/6Z)

TECH CENTER 1600  
 AUG 2 3 2003  
 100-300

RECEIVED

33.	EP	0 299 402	A2	ASTA Pharma Aktiengesellschaft	01-18-1989	A
34.	EP	0 331 983	A2	F. Hoffmann-La Roche AG	09-13-1989	A
35.	EP	0 402 232	A1	Rhone-Poulenc Sante	12-12-1990	A
36.	EP	0 532 156	A1	Matsuno et al.	03-17-1993	
37.	EP	0 579 915	A1	F. Hoffmann-La Roche AG	01-26-1994	A
38.	EP	0 702 962	A2	Eli Lilly and Company	03-27-1996	
39.	EP	0 703 239	A1	Hoechst Aktiengesellschaft	03-27-1996	A
40.	EP	0 716 086	A1	Boehringer Mannheim GMBH	06-12-1996	
41.	EP	0 743 070	A2	Trnka Mudr et al.	11-20-1996	A
42.	EP	0 758 649	A1	Kureha Chemical Industry Co., Ltd.	02-19-1997	
43.	EP	0 882 734	A2	F. Hoffman-La Roche AG	12-09-1998	
44.	EP	0 921 119	A1	ADIR Et Compagnie	06-09-1999	A
45.	GB	2 282 598	A	Merck & Co., Inc.	04-12-1995	
46.	WO	87/07609	A1	Taiho Pharmaceutical Co., Ltd.	12-17-1987	A
47.	WO	93/11145	A1	Banyu Pharmaceutical Co., Ltd.	06-10-1993	
48.	WO	93/18652	A1	Merck & Co.	09-30-1993	
49.	WO	93/20229	A1	Genentech, Inc.	10-14-1993	
50.	WO	94/02466	A1	The Du Pont Merck Pharmaceutical Company	02-03-1994	
51.	WO	94/12169	A1	Merck & Co., Inc.	06-09-1994	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED  
TECH CENTER 1600  
AUG 23 2003  
1600  
1600/2900

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**



as many sheets as necessary)

Sheet	4	of	13	Attorney Docket No.	PHA 4295 (3167/6Z)
-------	---	----	----	---------------------	--------------------

52.	WO	94/13635	A1	Merck Frosst Canada Inc.	06-23-1994
53.	WO	94/20480	A1	Merck Frosst Canada Inc.	09-15-1994
54.	WO	94/21612	A1	Otsuka Pharmaceutical Co., Ltd.	09-29-1994
55.	WO	94/25431	A1	The Wellcome Foundation Limited	11-10-1994
56.	WO	94/25466	A1	Glaxo, Inc.	11-10-1994
57.	WO	94/26731	A1	Merck Frosst Canada Inc.	11-24-1994
58.	WO	94/27980	A1	G.D. Searle & Co.	12-08-1994
59.	WO	95/02603	A2	Pharmacia S.P.A.	01-26-1995
60.	WO	95/08327	A1	The Government of the United States of America	03-30-1995
61.	WO	95/11883	A1	G.D. Searle & Co.	05-04-1995
62.	WO	95/12606	A1	The Wellcome Foundation Limited	05-11-1995
63.	WO	95/15316	A1	G.D. Searle & Co.	06-08-1995
64.	WO	95/24199	A2	Cell Therapeutics, Inc.	09-14-1995
65.	WO	95/28426	A2	La Jolla Cancer Research Foundation	10-26-1995
66.	WO	95/30652	A1	G.D. Searle & Co.	11-16-1995
67.	WO	95/30656	A1	G.D. Searle & Co.	11-16-1995
68.	WO	96/00574	A1	Smithkline Beecham Corporation	01-11-1996
69.	WO	96/00581	A1	Texas Biotechnology Corporation	01-11-1996
70.	WO	96/01653	A1	Board of Regents, The University of Texas System et al.	01-25-1996

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

O I P (See as many sheets as necessary)

AUG 15 2003  
PATENT & TRADEMARK OFFICE

Complete if Known

Application Number	09/857,994
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1646
Examiner Name	Unknown

Sheet	5	of	13	Attorney Docket No.	PHA 4295 (3167/6Z)
-------	---	----	----	---------------------	--------------------

71.	WO	96/03387	A1	G.D. Searle & Co.	02-08-1996
72.	WO	96/03392	A1	G.D. Searle & Co.	02-08-1996
73.	WO	96/06840	A1	Merck Frosst Canada Inc.	03-07-1996
74.	WO	96/14745	A1	The Regents of the University of California	05-23-1996
75.	WO	96/21667	A1	Merck Frosst Canada Inc.	07-18-1996
76.	WO	96/33988	A1	Wisconsin Alumni Research Foundation	10-31-1996
77.	WO	96/35774	A2	The Children's Medical Center Corporation	11-14-1996
78.	WO	96/36335	A1	Pharmacia S.P.A.	11-21-1996
79.	WO	96/36612	A1	Rutgers, The State University of New Jersey	11-21-1996
80.	WO	96/36622	A1	Indena S.P.A.	11-21-1996
81.	WO	96/36623	A1	Merck Frosst Canada Inc.	11-21-1996
82.	WO	96/37469	A1	Merck Frosst Canada Inc.	11-28-1996
83.	WO	97/08145	A1	G.D. Searle & Co.	03-06-1997
84.	WO	97/11718	A1	The Victoria University of Manchester	04-03-1997
85.	WO	97/15666	A1	The Children's Medical Center Corporation	05-01-1997
86.	WO	97/15676	A2	Abbott Laboratories	05-01-1997
87.	WO	97/19954	A1	Asta Medica Aktiengesellschaft	06-05-1997

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..


SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED  
TECH CENTER 1600  
AUG 2 3 2003  
16012800

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)



Sheet

6

of

13

Complete if Known		RECEIVED TECH CENTER 1600 AUG 2 3 2001 1600 1600 1600
Application Number	09/857,994	
Filing Date	October 5, 2000	
Confirmation Number	Unknown	
First Named Inventor	John P. McKearn et al.	
Group Art Unit	1646	
Examiner Name	Unknown	
Attorney Docket No.	PHA 4295 (3167/6Z)	

	88.	WO	97/20835	A1	Harbor Branch Oceanographic Institution, Inc.	06-12-1997	
	89.	WO	97/23451	A1	Merck Patent Gesellschaft Mit Beschränkter Haftung	07-03-1997	A
	90.	WO	97/23480	A1	The Du Pont Merck Pharmaceutical Company	07-03-1997	
	91.	WO	97/24116	A2	Allergan	07-10-1997	
	92.	WO	97/29106	A1	Rutgers, The State University of New Jersey	08-14-1997	
	93.	WO	97/31936	A2	Wisconsin Alumni Research Foundation	09-04-1997	
	94.	WO	97/33887	A1	The Du Pont Merck Pharmaceutical Company	09-18-1997	
	95.	WO	97/34608	A1	Mayo Foundation for Medical Education and Research	09-25-1997	
	96.	WO	97/36497	A2	Mars, Incorporated	10-09-1997	
	97.	WO	97/36860	A1	G.D. Searle & Co.	10-09-1997	
	98.	WO	97/36863	A1	Merck Frosst Canada Inc.	10-09-1997	
	99.	WO	97/37658	A1	Boehringer Mannheim Italia S.P.A.	10-16-1997	
	100.	WO	97/41844	A1	Alcon Laboratories, Inc.	11-13-1997	
	101.	WO	97/47296	A2	Mount Sinai Hospital Corporation	12-18-1997	
	102.	WO	97/49704	A1	Janssen Pharmaceutica N.V.	12-31-1997	
	103.	WO	98/03484	A1	Merck Frosst Canada Inc.	01-29-1998	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Complete if Known

RECEIVED  
TECH CENTER 1600  
AUG 2 3 2003  
1600  
600

Application Number	09/857,994
Filing Date	October 5, 2000
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1646
Examiner Name	Unknown

Sheet 7 of 13 Attorney Docket No. PHA 4295 (3167/6Z)

104.	WO	98/07432	A1	American Home Products Corporation	02-26-1998
105.	WO	98/07433	A1	Bristol-Myers Squibb Company	02-26-1998
106.	WO	98/12181	A1	Rutgers, The State University of New Jersey	03-26-1998
107.	WO	98/13350	A1	Zeneca Limited	04-02-1998
108.	WO	98/14188	A1	Ilex Oncology Inc.	04-09-1998
109.	WO	98/16227	A1	G.D. Searle & Co.	04-23-1998
110.	WO	98/22101	A2	G.D. Searle & Co.	05-28-1998
111.	WO	98/25603	A1	Ilex Oncology, Inc.	06-18-1998
112.	WO	98/25896	A1	G.D. Searle & Co.	06-18-1998
113.	WO	98/40104	A2	Yale University et al.	09-17-1998
114.	WO	98/45294	A1	Astra Pharmaceuticals Ltd.	10-15-1998
115.	WO	99/01131	A1	Smithkline Beecham Corporation	01-14-1999
116.	WO	99/05104	A1	Pfizer Pharmaceuticals Inc.	02-04-1999
117.	WO	99/10331	A1	Abbott Laboratories	03-04-1999
118.	WO	99/12930	A1	Glaxo Group Limited	03-18-1999
119.	WO	99/14194	A1	Merck Frosst Canada Inc.	03-25-1999
120.	WO	99/14205	A1	Almirall Prodesfarma S.A.	03-25-1999
121.	WO	99/21583	A1	Warner-Lambert Company	05-06-1999
122.	WO	99/23087	A1	Merck Frosst Canada & Co.	05-14-1999

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Use as many sheets as necessary

SEARCHED *TECH CENTER 1600*  
AUG 15 2003  
PATENT & TRADEMARK OFFICE  
RECEIVED *AUG 2 2003*

Sheet	8	of	13	Attorney Docket No.	PHA 4295 (3167/6Z)
-------	---	----	----	---------------------	--------------------

	123.	WO	99/31067	A1	Rutgers, The State University of New Jersey	06-24-1999	
	124.	WO	99/41241	A1	Rutgers, The State University of New Jersey	08-19-1999	

## OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	125.	BARNI, S., et al., Clinical Efficacy of the Aromatase Inhibitor Anastrozole in Relation to Prolactin Secretion in Heavily Pretreated Metastatic Breast Cancer, Tumouri, Jan.-Feb. 1998, pp. 45-47, Vol. 84(1)	
	126.	BENSON, J.R., et al., Tamoxifen, Biologic Therapy of Cancer: Principles and Practice, 1997, pp. 817-828, Vol. One, Ch. 29, J.F. Holland et al. (Eds.), Baltimore, MD	
	127.	BREMBECK, F.H., et al., A Phase II Pilot Trial of 13-cis Retinoic Acid and Interferon- $\alpha$ in UICC Stage III/IV Pancreatic Cancer, Gastroenterology Oncology, April 1998, Abstract G2329, Vol. 114, No. 4, Pt. 2, A569	
	128.	BREMBECK, F.H., et al., A Phase II Trial of 13-cis Retinoic Acid and Interferon- $\alpha$ in Patients with Advanced Pancreatic Carcinoma, Cancer, 1998, pp. 2317-2323, Vol. 83, No. 11	
	129.	BROOKS, P.C., et al., Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels, Cell, Dec. 30, 1994, pp. 1157-1164, Vol. 79	
	130.	CAO, Y., et al., Kringle Domains of Human Angiostatin, The Journal of Biological Chemistry, Nov. 15, 1996, pp. 29461-29467, Vol. 271, No. 46	
	131.	DONG, Z., et al., Macrophage-Derived Metalloelastase is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma, Cell, Mar. 21, 1997, pp. 801-810, Vol. 88	
	132.	DRUMMOND, A.H., et al., Preclinical and Clinical Studies of MMP Inhibitors in Cancer, Annals of the New York Academy of Science, June 1999, pp. 228-235, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	


Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

RECEIVED  
TECH CTR  
AUG 15 2003  
1646  
2003  
00000000

Application Number	09/857,994
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKeart et al.
Group Art Unit	1646
Examiner Name	Unknown

Sheet	9	of	13	Attorney Docket No.	PHA 4295 (3167/6Z)
-------	---	----	----	---------------------	--------------------

133.	DURANDO, A., et al., Combination chemotherapy with paclitaxel (T) and epirubicin (E) for metastatic breast cancer (MBC): A phase I-II study, European Journal of Cancer, Sept. 30, 1998, pp. S12-13, Abstract 41	
134.	FAN, T.-P.D., et al., Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy, Trends Pharmacol.Sci. Feb. 1995, pp. 57-66, Vol. 16	
135.	FISHER, J.E., et al., Inhibition of Osteoclastic Bone Resorption In Vivo by Echistatin, An, "Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein, Endocrinology, 1993, pp. 1411-1413, Vol. 132, No. 3	
136.	FORMENTI, C., et al., Concurrent paclitaxel and radiation in locally advanced breast cancer, European Journal of Cancer, Sept. 30, 1998, p. S12, Abstract 39	
137.	GALARDY, R.E., et al., Inhibition of Angiogenesis by the Matrix Metalloprotease Inhibitor <i>N</i> -[2R-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide, Cancer Research, Sept. 1, 1994, pp. 4715-4718, Vol. 54	
138.	GIANNIS, A., et al., Integrin Antagonists and Other Low Molecular Weight Compounds as Inhibitors of Angiogenesis: New Drugs in Cancer Therapy, Angew. Chem. Int. Ed. Engl., 1997, pp 588-590, Vol. 36, No. 6	
139.	GUTTERMAN, J.U., Cytokine Therapeutics: Lessons from interferon $\alpha$ , Proc. Natl. Acad. Sci., USA, Feb. 1994, pp. 1198-1205, Vol. 91	
140.	HANDSCHUMACHER, R.E., et al., Purine and Pyrimidine Antimetabolites, Chemotherapeutic Agents, pp. 712-732, Ch. XV1-2, 3rd Edition, Edited by J. Holland, et al., Lea and Febigol, publishers	
141.	IHDE, D.C., M.D., Current Status of Therapy for Small Cell Carcinoma of the Lung, Cancer, Dec. 1, 1984 Supplement, pp. 2722-2728, Vol. 54	
142.	International Search Report for Application No. PCT/US99/30670, dated September 5, 2000	
143.	JAYSON, G.C., ET AL., A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer, British Journal of Cancer, 1998, pp. 366-369, Vol. 78(3)	
144.	JOSS, R.A., et al., New agents in non-small cell lung cancer, Cancer Treatment Reviews, 1984, pp. 205-236, Vol.11	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

O I P B U S A  
AUG 15 2003  
P A T E N T & T R A D E M A R K O F F I C E

Sheet	10	of	13	Attorney Docket No.	PHA 4295 (3167/6Z)
-------	----	----	----	---------------------	--------------------

145.	KROWN, S.E., The Role of Interferon in the Therapy of Epidemic Kaposi's Sarcoma, Seminars in Oncology, June, 1987, pp.27-33, Vol. 14, No. 2, Suppl. 3
146.	LINGEN, M.W., et al., Retinoic Acid and Interferon $\alpha$ Act Synergistically as Antiangiogenic and Antitumor Agents against Human Head and Neck Squamous Cell Carcinoma, Cancer Research, Dec. 1, 1998, pp. 5551-5558, Vol. 58
147.	LODE, H.N., et al., Synergy between an antiangiogenic integrin $\alpha_v$ antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases, Proc. Nat. Acad. Sci. USA., Feb. 1999, pp. 1591-1596, Vol. 96
148.	LOKESHWAR, B.L, MMP Inhibition in Prostate Cancer, Annals of the New York Academy of Science, June 1999, pp. 271-289, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)
149.	MACKEAN, M.J., et al., A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma, British Journal of Cancer, 1998, pp. 1620-1623, Vol. 78(12)
150.	MAIONE, T.E., et al., Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides, Science, Jan. 5, 1990, pp. 77-79, Vol. 247
151.	MAJEWSKI, S., et al., Synergistic Anticancer Action of Retinoids, Vitamin D3 and Cytokines (Interferons and Interleukin-12) as Related to the Antiangiogenic and Antiproliferative Effects, J.Invest.Dermatol., April 1997, Abstract 202, Vol. 108, No. 4
152.	MONTGOMERY, A.M.P., et al., Integrin $\alpha_v\beta_3$ rescues melanoma cells from apoptosis in three-dimensional dermal collagen, Proc. Natl. Acad. Sci. USA, Sept. 1994, pp. 8856-8860, Vol. 91
153.	MOON, R.C., et al., N-(4-Hydroxyphenyl)retinamide, A New Retinoid for Prevention of Breast Cancer in the Rat, Cancer Research, April 1979, pp. 1339-1346, Vol. 39
154.	MÜLLER, H., Antio-genesis-inhibition and intra-arterial chemotherapy - A new modality treatment for advanced and metastatic pancreatic carcinoma, Eur.J.Cancer 33, 1997, Abstract 215, p. S50, Suppl. 8
155.	NAITO, K., et al., Inhibition of Growth of Human Tumor Cells in Nude Mice by a Metalloproteinase Inhibitor, Int. J. Cancer, 1994, pp. 730-735, Vol 58

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED  
TECH CENTER 1600  
AUG 23 2003

<b>Complete if Known</b>	
Application Number	09/857,994
Filing Date	October 5, 2000
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1646
Examiner Name	Unknown

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

RECEIVED  
TECH CENTER 1600  
AUG 20 2003  
1600  
AUG 15 2003  
O I P E  
U S P T O  
P A T E N T & T R A D E M A R K S  
O F F I C E

Application Number	09/857,994
Filing Date	October 5, 2000
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1646
Examiner Name	Unknown

Sheet 11 of 13 Attorney Docket No. PHA 4295 (3167/6Z)

156.	NERI, A., et al., Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in the lung after IV-tail vein implantation in C57BL/6 mice, Proceedings of the American Association for Cancer Research, Mar. 1998, p. 302, Abstract 2060, Vol. 39	
157.	O'REILLY, M.S., et al., Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth, Cell, Jan. 24, 1997, pp. 277-285, Vol. 88	
158.	OSAKI, A., et al., A combination therapy with mitomycin-C, etoposide, doxifluridine and medroxyprogesterone acetate as second-line therapy for advanced breast cancer, European Journal of Cancer, Sept. 30, 1998, p. S16, Abstract 56	
159.	PFAFF, M., et al., Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by $\alpha$ IIb $\beta$ 3, $\alpha$ V $\beta$ 3, and $\alpha$ 5 $\beta$ 1 Integrins, The Journal of Biological Chemistry, Aug. 12, 1994, pp. 20233-20238, Vol. 269, No. 32	
160.	POWLES, T.J., II. Tamoxifen's Oestrogen-like Effects in a Breast Cancer Chemoprevention Trial, European Journal of Cancer, 1998, pp. S17-S18, Vol. 34, Suppl. 4, printed in Great Britain	
161.	RAVAUD, A., et al., Subcutaneous Interleukin-2, Interferon Alfa-2a, and Continuous Infusion of Fluorouracil in Metastatic Renal Cell Carcinoma: A Multicenter Phase II Trial, Journal of Clinical Oncology, Aug. 1998, pp. 2728, 2732, Vol. 16, No. 8	
162.	ROSENBERG, S.A., et al., Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b, Journal of Clinical Oncology, Mar. 1999, pp. 968-975, Vol. 17, No. 3	
163.	RYAN, C.W., et al., A Phase II Trial of Outpatient Subcutaneous GM-CSF, Interleukin-2, and Interferon-Alpha Plus Oral cis-Retinoic Acid in Patients with Metastatic Renal Cell Cancer, J.Invest.Med., 1998, p. 274A, Vol. 46, No. 7	
164.	SCHACHTER, J., et al., A Sequential Four-drug Chemotherapy and Biotherapy with Interferon Alpha and GM-CSF - An Innovative Protocol for the Treatment of Metastatic Melanoma, Cancer Biotherapy & Radiopharmaceuticals, 1998, pp. 155-164, Vol. 13, No. 3	
165.	SEFTOR, R.E.B., et al., Role of the $\alpha$ <sub>v</sub> $\beta$ <sub>3</sub> integrin in human melanoma cell invasion, Proc. Natl. Acad. Sci. USA, Mar. 1992, pp. 1557-1561, Vol. 89	

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED  
TECH CENTER 1600/2003  
AUG 20 2003

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



12

of

13

<i>Complete if Known</i>	
Application Number	09/857,994
Filing Date	October 5, 2001
Confirmation Number	Unknown
First Named Inventor	John P. McKearn et al.
Group Art Unit	1646
Examiner Name	Unknown
Attorney Docket No.	PHA 4295 (3167/6Z)

	166.	SHALINSKY, et al., Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials, Annals of the New York Academy of Science, June 1999, pp. 236-270, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	
	167.	SILBER, R., et al., DNA Topoisomerase I Inhibitors, Purine and Pyrimidine Antimetabolites, Chemotherapeutic Agents, pp. 779-782, Ch. XV1-7, 3rd Edition, Edited by J. Holland, et al., Lea and Febigol, publishers	
	168.	SOORI, G.S., et al., Phase II Study of Chemo-Biotherapy with Chlorambucil and Alpha Interferon in Patients with Non-Hodgkin's Lymphoma (NHL), Abstract #4032, Blood, 1998, pp. 240b, Vol. 92, No. 10	
	169.	STADLER, W.M., et al., Multicenter Phase II Trial of Interleukin-2, Interferon- $\alpha$ , and 13-cis-Retinoic Acid in Patients With Metastatic Renal-Cell Carcinoma, Journal of Clinical Oncology, May 1998, pp.1820-1825, Vol. 16, No. 5	
	170.	STRAUSS, G.M., et al., Multimodality Treatment of Stage IIIA Non-Small-Cell Lung Carcinoma: A critical Review of the Literature and Strategies for Future Research, Journal of Clinical Oncology, May, 1992, pp. 829-838, Vol. 10, No. 5	
	171.	SUH, N., et al., Novel Triterpenoids Suppress Inducible Nitric Oxide Synthase (iNOS) and Inducible Cyclooxygenase (COX-2) in Mouse Macrophages <sup>1</sup> , Cancer Research, Feb. 15, 1998, pp. 717-723, Vol. 58	
	172.	TAKADA, Y., et al., Structures and functions of integrins, Jikken Igaku, 1996, pp. 2317-2322, Vol. 14 (17), English Abstract from SciFinder, Nov. 29, 2001, p. 3	A
	173.	TEICHER, B.A., et al., Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma, Breast Cancer Research and Treatment, 1995, pp. 227-236, Vol. 36	
	174.	TEICHER, B.A., et al., TNP-470/Minocycline/Cytotoxic Therapy: A Systems Approach to Cancer Therapy, European Journal of Cancer, 1996, pp. 2461-2466, Vol. 32A, No. 14	
	175.	THOMAS, C.A., et al., High-Dose Methotrexate (HD-MTX) Monotherapy in Patients with CNS Non-Hodgkin's Lymphoma, Blood, 1998, Abstract #4033, pp. 240b, Vol. 92, No. 10	

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Use as many sheets as necessary

Sheet	13	of	13	Attorney Docket No.	PHA 4295 (3167/6Z)
-------	----	----	----	---------------------	--------------------

176.	TOLLSMA, S.S., et al., Peptides Derived from Two Separate Domains of the Matrix Protein Thrombospondin-1 Have Anti-Angiogenic Activity, The Journal of Cell Biology, 1993, pp. 497-511, Vol. 122	
177.	TOURANI, J.-M., et al., Outpatient Treatment With Subcutaneous Interleukin-2 and Interferon Alfa Administration in Combination With Fluorouracil in Patients With Metastatic Renal Cell Carcinoma: Results of a Sequential Nonrandomized Phase II Study, Journal of Clinical Oncology, July 1998, pp. 2505-2513, Vol. 16, No. 7	
178.	TUSZYNSKI, G.P., et al., The role of thrombospondin-1 in tumor progression and angiogenesis, Bioessays, 1996, pp. 71-76, Vol. 18, No. 1	
179.	VARNER, J.A., et al., Tumor Angiogenesis and the Role of Vascular Cell Integrin $\alpha v \beta 3$ , J. Mol. Biol., 1996, pp. 69-87	
180.	ZUCKER, S., Experimental Models to Identify Antimetastatic Drugs: Are We There Yet?, A Position Paper, Annals of the New York Academy of Science, June 1999, pp. 208-211, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	
181.	ZUCKER, S., et al., Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues, Clinical and Experimental Applications, Annals of the New York Academy of Science, June 1999, pp. 212-227, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.)	

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED  
TECH CENTER 1600  
AUG 7 2003  
AUG 15 2003